Paul L. Gittelson
President, BioResearch Monitors, Inc.

Paul Gittelson has over 25 years experience in industrial pharmaceutical research and development.

Prior to joining BioResearch Monitors, Inc., Mr. Gittelson was Associate Director, Worldwide Regulatory Compliance, Bristol-Myers Squibb Company, Pharmaceutical Research Institute, where for 15 years he managed Quality Assurance and Regulatory Compliance activities relating to Clinical Investigations (Good Clinical Practices - GCP's), Test Article production for use in clinical and nonclinical studies (Good Manufacturing Practices - GMP's), and Nonclinical Laboratory (Safety/Toxicology) Studies (Good Laboratory Practices - GLP's).

Mr. Gittelson received the B.A. and M.A. degrees in Physiological Psychology from the State University of New York at Binghamton. He has organized and participated in numerous conferences and seminars on research quality assurance. He has been active in various drug industry professional organizations and is past chairman of the Pharmaceutical Manufacturers Association BioResearch Monitoring Subcommittee.

Gary T. Sniffen
Vice President, BioResearch Monitors, Inc.

Gary Sniffen has over 20 years experience in Quality Assurance of clinical pharmaceutical research and development.

Prior to joining BioResearch Monitors, Inc., Mr. Sniffen was Senior Compliance Auditor, Worldwide Regulatory Compliance, Bristol-Myers Squibb Company, Pharmaceutical Research Institute. In his capacity, Mr. Sniffen planned, supervised and conducted Good Clinical Practices (GCP's) Quality Assurance/Regulatory Compliance evaluations of clinical trials.

Mr. Sniffen received a B.S. degree in Biology from LeMoyne College and a B.S. degree in Medical Technology from State University of New York, Upstate Medical Center (Health Science Center) in Syracuse N.Y. He is an Associate Member of the American Society of Clinical Pathologists (ASCP) and an ASCP registered Medical Technologist.

Mr. Sniffen has extensive experience in evaluating both domestic and multi-national clinical trials.